The IMvigor 210 study [37] demonstrated a greater benefit of treatment with atezolizumab, a PD-L1-blocking antibody, in advanced BC classified as TCGA cluster II [7], and in the CheckMate 275 study, basal tumors responded better to nivolumab, a PD-1-blocking antibody [38]. Here, CD274 is linked to breast cancer.